These findings suggest that patient age and liver inflammation markers, such as baseline ALT and AST levels, play a crucial role in determining the efficacy of traditional probiotics for treating NAFLD/NASH. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.